Author:
Phua Lee Cheng,Goh Shixu,Tai David Wai Meng,Leow Wei Qiang,Alkaff Syed Muhammad Fahmy,Chan Chung Yip,Kam Juinn Huar,Lim Tony Kiat Hon,Chan Eric Chun Yong
Funder
Singapore General Hospital Research Grant
Singapore Ministry of Education Tier 1 Grant
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference43 articles.
1. Ferlay J SI, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2013) GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer.
http://globocan.iarc.fr
. Accessed 11 Aug 2014
2. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15(6):2403–2413
3. Voutsadakis IA (2011) Molecular predictors of gemcitabine response in pancreatic cancer. World J Gastrointest Oncol 3(11):153–164.
https://doi.org/10.4251/wjgo.v3.i11.153
4. Ryan DP G-CR, Chabner BA (2006) Cytidine analogues. In: Cancer chemotherapy and biotherapy, 4th edn. Lippincott Williams and Wilkins, Philadelphia, pp 183–211
5. Farrell JJ, Elsaleh H, Garcia M, Lai R, Ammar A, Regine WF, Abrams R, Benson AB, Macdonald J, Cass CE, Dicker AP, Mackey JR (2009) Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 136(1):187–195.
https://doi.org/10.1053/j.gastro.2008.09.067
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献